Stocks
Denali Therapeutics (DNLI) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 1 079% | 6 870% | 3 122% | 2 012% | 3 276% | 3 268% | |||
| Changes by years, y/y, % | -3 141pp | +5 790pp | -3 748pp | -1 110pp | +1 264pp | -4.9% | |||
Denali Therapeutics. R&D/CAPEX, %
Denali Therapeutics. R&D/CAPEX, changes, pp
Denali Therapeutics (DNLI) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| R&D/CAPEX, % | 4 624% | 1 667% | 4 339% | 4 823% | 4 977% | 3 268% | ||
| Changes by years, y/y, % | +2 493pp | -1 539pp | +2 888pp | +2 924pp | +354pp | |||
| Changes by quarters, q/q, % | +2 724pp | -2 957pp | +2 672pp | +484pp | +154pp | |||
